Myovant Sciences
Women’s health and endocrine diseases medicines. Subsidiary of Roivant.
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 18 % | 293 % | 75 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (546 %) | (437 %) | (74 %) | (32 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (578 %) | (432 %) | (79 %) | (27 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Myovant Sciences is a biopharmaceutical company dedicated to redefining care for women and men through purpose-driven science, empowering medicines, and transformative advocacy. The company focuses on developing innovative treatments for uterine fibroids, endometriosis, and prostate cancer, aiming to improve the lives of millions affected by these conditions. Myovant operates in the healthcare market, primarily serving patients and healthcare providers. Its business model revolves around the research, development, and commercialization of novel therapies. Revenue is generated through the sale of these medicines, as well as potential partnerships and collaborations with other pharmaceutical companies. Myovant's pipeline includes promising drug candidates that address significant unmet medical needs, positioning the company as a key player in the biopharmaceutical industry.
Keywords: biopharmaceutical, uterine fibroids, endometriosis, prostate cancer, innovative medicines, healthcare, research, development, commercialization, transformative advocacy.